On 08 November 2018
Glenmark Pharmaceuticals announced to launch a Phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342. GBR 1342 is based on Glenmark's proprietary BEAT platform and simultaneously targets CD38 and the CD3 T cell co-receptor. CD38 is an antigen known to be implicated in hematological malignancies as well as some solid tumors. The company seeks filing an Investigational New Drug (IND) application for GBR 1342 in solid tumors and initiate a clinical trial in 2019. An ongoing first-in-human, open-label, Phase 1 trial of GBR 1342 in multiple myeloma (NCT03309111), is assessing the safety and tolerability of increasing doses of GBR 1342, and will also evaluate biomarkers, immunogenicity, and additional measures of disease activity.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
